Phase I/II study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer

Japanese Journal of Lung Cancer

Volumn 44, Issue 2, 2004, Pages 77-82

  Ohashi, Nobuyuki ^a   Daga, Haruko ^a   Nishino, Ryohei ^a   Mito, Akiko ^a   Moritani, Chie ^a   Takakura, Rumie ^b   Taooka, Yasuyuki ^c   Nakamura, Kenji ^d   Daido, Kazuhiro ^e   Arita, Ken Ichi ^a  

^a ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^b Mihara City Med Assoc Hospital   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e Daido Clinic   (Japan)

Author keywords

Carboplatin; Chemotherapy; Non small cell lung cancer; Weekly paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYPONATREMIA; INFECTION; LETHARGY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 3242743076     PISSN: 03869628     EISSN: None     Source Type: Journal    
DOI: 10.2482/haigan.44.77     Document Type: Article

References (21)

1. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:621-631.
2. Yana T, Takada M, Origasa H, et al. New chemotherapy agent plus platinum for advanced non-small cell lung cancer: a meta-analysis. Proc Am Soc Clin Oncol. 2002;22:328a.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
4. Klaassen U, Wilke H, Strumberg D, et al. Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer. 1996;32:547-549.
5. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997;15:187-192.
6. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13:1860-1870.
7. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-3218.
8. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol. 1995;13:180-190.
9. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16:3353-3361.
10. Glantz MJ, Choy H, Akerley W, et al. Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol. 1996;23 (suppl 16):128-135.
11. Tamura T, Sasaki Y, Nishiwaki Y, et al. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion in one of the major dose-limiting toxicities. Jpn J Cancer Res. 1995;86:1203-1209.
12. Andersson H, Boman K, Ridderheim M, et al. An updated analysis of a randomized study of single agent paclitaxel given weekly vs every 3 weeks to patients with ovarian cancer treated with prior platinum therapy. Proc Am Soc Clin Oncol. 2000;19:380a.
13. Huang CH, Langer CJ, Minniti C, et al. Phase III toxicity trial of carboplatin plus either docetaxel or paclitaxel in advanced non-small cell lung cancer: preliminary findings of OPN-001. Proc Am Soc Clin Oncol. 2002;21:337a.
14. Ohe Y, Saijo N, Ohashi Y, et al. Preliminary results of the Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer in Japan. Proc Am Soc Clin Oncol. 2003;22:624.
15. Chang AY, Rubins J, Asbury R, et al. Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol. 2001;28(suppl 14):10-13.
16. Koumakis G, Demiri M, Barbounis V, et al. Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial. Lung Cancer. 2002;35:315-317.
17. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 1998;16:153-158.
18. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003;21:2933-2939.
19. Ukena D, Schroeder M, Dittrich I, et al. Phase III randomised trial comparing paclitaxel/carboplatin every 3 weeks with weekly paclitaxel/ carboplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 2003;22:623.